Table 4.
Comparison of current study results to previous research regarding influenza vaccination rates, influenza-related hospitalizations, and influenza-positive rates. CI is confidence interval; SCD, sickle cell disease; BMC, Boston Medical Center; EHR, electronic health record.
| Population | Age range | Rate | Data source | Study year(s) | |
|---|---|---|---|---|---|
| Influenza vaccination rate | BMC pediatric SCD patients | 1–17 years | 90.32% | EHR-based SCD registry | 2019–2020 |
| BMC pediatric SCD patients19 | 6 months–21 years | 44.91% | EHR-based SCD registry | 2011–2012 | |
| BMC pediatric SCD patients19 | 6 months–21 years | 80.49% | EHR-based SCD registry | 2012–2013 | |
| BMC pediatric SCD patients19 | 6 months–21 years | 90.42% | EHR-based SCD registry | 2013–2014 | |
| Individuals with asthma in the US20 | 0–17 years | 63.70% (95% CI: 60.6%−66.7%) | Survey of parents | 2012–2014 | |
| General US population21 | 6 months – 17 years | 62.60% (95% CI: 61.9%−63.3%) | Survey of household adults/parents | 2018–2019 | |
| Pediatric SCD patients22 | 6 months – 17 years | 43% (No CI provided) | Medical records | 2000–2001 | |
| Pediatric SCD patients22 | 6 months – 17 years | 76% (No CI provided) | Medical records | 2005–2006 | |
| Pediatric SCD patients7 | 2–5 years | 41% (No CI provided) | Maryland Medicaid claims data | 2002–2008 | |
| Pediatric SCD patients23 | 4 months – 15 years | 8% (No CI provided) | Hospital notes and local general practitioners | 2007–2008 | |
| Pediatric asthma patients24 | 2–14 years | 62.04% (No CI provided) | Prospective nonrandomized controlled trial | 1992–1993 | |
| Children with SCD25 | 6 months - unspecified | ≈45%−55% (No CI provided) | Survey of parents/caregivers | 2011–2012 | |
| Children with asthma25 | 6 months-unspecified | ≈55–65% (No CI provided) | Survey of parents/caregivers | 2011–2012 | |
| Influenza-related hospitalizations | BMC pediatric SCD patients | 1–17 years | 0 | EHR-based SCD registry | 2019–2020 |
| Pediatric asthma patients13 | 6 – 59 months | 1.00 (95% CI: 0.30–1.80) case per 1,000 children | Prospective, population-based study | 2000–2004 | |
| Pediatric SCD patients10 | 0–17 years | 11.20 per 1,000 children (No CI provided) | Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SIDs) | 2003–2005 | |
| General population26 | 5–17 years | 0.41 per 1,000 population (No CI provided) | Influenza Hospitalization Surveillance Network (FluSurv-NET) data | 2019–2020 | |
| General population27 | 7–11 years | 0.23 (95% CI:0.185–0.277) per 1,000 children | Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SIDs) | 2003–2010 | |
| Pediatric asthma patients27 | 7–11 years | 0.073 (95% CI:0.045 – 0.102) per 1,000 children | Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SIDs) | 2003–2010 | |
| Influenza-positive rates | BMC pediatric SCD patients | 1–17 years | 4.84% | EHR-based SCD registry | 2019–2020 |
| SCD patients28 | 6 months – 21 years | 29.60% (No CI provided) | Children’s Healthcare of Atlanta Sickle Cell Disease Clinical Database (SCDCD) | 2012–2017 | |
| General population29 | 0–17 years | 9.30% (95% CI, 8.20% – 11.10%) | Influenza Hospitalization Surveillance Network (FluSurv-NET) with additional calculations | 2010–2016 | |
| Pediatric asthma patients24 | 2–14 years | 52.55% (No CI provided) | Prospective nonrandomized controlled trial | 1992–1993 |